This site contains information for UK healthcare professionals only on Xolair and chronic spontaneous urticaria.
Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1
*Post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.2
DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E.
- Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
- Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.